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 Abstract
Clofazimine (CFZ) is an optically active, red-colored chemotherapeutic agent that is FDA
approved for the treatment of leprosy and is on the World Health Organization’s list of
essential medications. Interestingly, CFZ massively accumulates in macrophages where it
forms crystal-like drug inclusions (CLDIs) after oral administration of the drug in animals
and humans. The analysis of the fluorescence spectra of CLDIs formed by resident tissue
macrophages revealed that CFZ, when accumulated as CLDIs, undergoes a red shift in flu-
orescence excitation (from Ex: 540–570 to 560–600 nm) and emission (Em: 560–580 to
640–700 nm) signal relative to the soluble and free-base crystal forms of CFZ. Using epi-
fluorescence microscopy, CLDI(1) cells could be identified, relative to CLDI(2) cells,
based on a >3-fold increment in mean fluorescence signal at excitation 640 nm and emis-
sion at 670 nm. Similarly, CLDI(1) cells could be identified by flow cytometry, based on
a >100-fold increment in mean fluorescence signal using excitation lasers at 640 nm and
emission detectors >600 nm. CLDI’s fluorescence excitation and emission was orthogonal
to that of cell viability dyes such as propidium iodide and 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI), cellular staining dyes such as Hoechst 33342 (nucleus) and FM
1-43 (plasma membrane), as well as many other fluorescently tagged antibodies used for
immunophenotyping analyses. In vivo, >85% of CLDI(1) cells in the peritoneal exudate
were F4/80(1) macrophages and >97% of CLDI(1) cells in the alveolar exudate were
CD11c(1). Most importantly, the viability of cells was minimally affected by the presence
of CLDIs. Accordingly, these results establish that CFZ fluorescence in CLDIs is suitable
for quantitative flow cytometric phenotyping analysis and functional studies of xenobiotic
sequestering macrophages. VC 2015 International Society for Advancement of Cytometry
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MAMMALIAN organisms possess various passive and active transport mechanisms
that mediate the transport, distribution, and elimination of foreign chemical agents
such as environmental pollutants, toxicants, as well as pharmaceutical agents,
referred to as “xenobiotics.” Many xenobiotics are eliminated from the organism
through a combination of excretory and metabolic pathways but there are some that
are highly stable and therefore can bioaccumulate in the organism upon prolonged
exposure. Although these agents could potentially disrupt the normal physiological
functions of cells and organs, organisms may also possess active cellular mechanisms
that allow them to adapt to bioaccumulating chemical agents. In the latter category,
several weakly basic drug molecules have been shown to accumulate in macrophages
and some form aggregates with cellular membranes, whereas others precipitate as
insoluble intracellular complexes. Clofazimine (CFZ) is a model xenobiotic—a
weakly basic, FDA approved drug for the treatment of leprosy (1) that accumulates
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in macrophages, forming crystal-like drug inclusions (CLDIs)
(2–7). After biochemical isolation, it is possible to analyze the
composition of CLDIs, and we have elucidated that CLDIs are
composed of domains of pure CFZ hydrochloride crystals
(CFZ-HCl), bound and separated by membranes likely of cel-
lular origin (8).
Previously, bioaccumulation of uric acid crystals in mac-
rophages and the phagocytosis of silica particles have been
linked to the activation of proinflammatory signaling path-
ways in macrophages (9–12). Considering that CFZ possesses
immunomodulatory activity (2,13,14), we decided to deter-
mine whether CLDIs may elicit similar changes in macro-
phage function by developing a method by which CLDI-
containing macrophages could be isolated and functionally
studied. As in solution, CFZ is weakly fluorescent and its fluo-
rescence is pH sensitive as per the local microenvironment
(5,15), we sought to determine whether the formation of
CLDIs in macrophages is associated with specific shifts in the
fluorescence excitation and emission spectra that could be
used to detect CLDI-containing macrophages. Here, we report
how CLDI formation leads to a far-red shift in CFZ’s fluores-
cence signal, that is distinctively different from the fluores-
cence of soluble CFZ as well as free-base CFZ crystals (CFZ-
TC). Additional experiments demonstrate how this far-red
shift in fluorescence of CLDI-containing macrophages facili-




Mice (4-week old, male C57Bl6) were purchased from
the Jackson Laboratory (Bar Harbor, ME) and acclimatized
for 1 week in a specific pathogen-free animal facility. Animal
care was provided by the University of Michigan’s Unit for
Laboratory Animal Medicine (ULAM) and the experimental
protocol was approved by the Committee on Use and Care of
Animals in accordance with NIH guidelines. An oral diet con-
taining CFZ was fed to mice as described previously (2,3,8).
CFZ (C8895; Sigma-Aldrich, St. Louis, MO) was dissolved in
sesame oil (Roland, China, or Shirakiku, Japan) to achieve a
concentration of 3 mg/mL, which was mixed with Powdered
Lab Diet 5001 (PMI International, St. Louis, MO) to produce
a 0.03% drug to powdered feed mix. A corresponding amount
of sesame oil was mixed with chow for vehicle treatment (con-
trol mice). On average, food consumption for a 25-g mouse
was 3 g per day, resulting in 10 mg of bioavailable drug/kilo-
gram per day. For CFZ treatment, the drug diet was adminis-
tered for 8 weeks followed by regular chow for 8 weeks
(washout phase).
Isolation of CLDIs from Mouse Spleen
At 8 weeks post-drug feeding, mice were euthanized by
exsanguination while deeply anesthetized by an intraperito-
neal injection of ketamine (100 mg/kg)/xylazine (10 mg/kg)
and spleens were harvested and cut open to prepare tissue
homogenate in phosphate-buffered saline (PBS). The tissue
homogenate was sonicated for 30 min and centrifuged (100g
for 1 min) to remove large cell debris. A solution of 10%
sucrose in PBS was added to the acquired supernatant and the
mixture was centrifuged (100g). The resulting supernatant
was centrifuged (21,000g for 1 min) to pellet drug inclusions
which were then resuspended in 2 mL of 10% sucrose. CLDIs
were further purified using a three-layer discontinuous gradi-
ent (50, 30, and 10% sucrose in PBS) centrifugation method
(3,200g for 30 min, no brakes) (14). The CFZ content of the
isolated CLDIs was determined spectrophotometrically
(k5 495 nm) by procuring 100 lL of CLDIs (in triplicate) by
centrifugation (21,000g for 1 min) and dissolution in DMSO
followed by comparison with calibrated CFZ standards.
Fluorimetry
CFZ was dissolved in DMSO to achieve a concentration
of 20 lM. Fluorescence excitation and emission scans were
taken in increments of 10 nm from 400 to 800 nm on a
Perkin-Elmer LS-55 fluorescence spectrometer using standard
cuvettes. Data were imported into Microsoft
VR
Excel (Red-
mond, WA) (MS-Excel) for further analysis. The fluorescence
yield was background subtracted using data obtained from
solvent alone (DMSO) and was normalized to the maximum
fluorescence yield measured across the spectral wavelength
range tested.
Spectral Confocal Microscopy
For the preparation of slides, CFZ drug crystals were
dusted on a glass slide followed by the application of a glass
cover slip. For slides of CLDIs, a 20-lL drop of purified CLDIs
was placed on a glass slide and allowed to dry overnight in the
dark. The following day, a single drop of Prolong
VR
Gold (Life
Technologies, Carlsbad, CA) was added to the CLDIs and a
cover slip was applied prior to imaging. Spectral confocal
microscopy was performed on a Leica Inverted SP5X confocal
microscope system with two-photon FLIM (Leica Microsys-
tems, Buffalo Grove, IL) using excitation wavelengths
(k5 470–670 nm). Image analysis and quantification was per-
formed on Leica LAS AF. Several regions of interest of individ-
ual crystals were used to obtain fluorescence data which were
imported into MS-Excel for further analysis. All fluorescence
yields were normalized to the maximum fluorescence yield
measured across the spectral range tested and background
subtracted using data obtained from a blank slide.
Epifluorescence Microscopy
Visualization of all samples (cells or crystals) was done on
a Nikon Eclipse Ti (Nikon Instruments, Melville, NY). The flu-
orescence filters (excitation/emission) used were optimized for
4,6-diamidino-2-phenylindole dihydrochloride (DAPI) (350/
405 nm, exposure5 50 ms), fluorescein isothiocyanate (FITC)
(490/510 nm, exposure5 100–500 ms), Texas Red (590/
610 nm, exposure< 500 ms), and Cy5 (640/670 nm,
exposure5 15 ms). Brightfield color photographs were
acquired using a Nikon DS-Fi2 camera, whereas fluorescence




MYO (Photometrics, Tucson, AZ) camera. CLDIs (seen as
intense red pigmentation) were counted and analyzed for
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physical dimensions using the Nikon Elements software (Nikon
Instruments, Melville, NY).
Identification of the CLDI Signal by Flow Cytometry in
RAW 264.7 Cells
Macrophages phagocytose CLDIs isolated from the mouse
spleen after 8 weeks of CFZ treatment (14). RAW 264.7 cells
(TIB-71
TM
ATCC, Manassas, VA) cells were maintained with
DMEM1 10% fetal bovine serum (FBS) (10082; GibcoV
R
, Invi-
trogen, Carlsbad, CA) with 1% of penicillin/streptomycin
(15140; Gibco
VR
, Invitrogen, Carlsbad, CA) at 378C, 5% CO2.
The cells were seeded at 4 3 105 cells/well in a six-well plate
18–20 h prior to incubation with isolated and purified spleen
CLDIs at a solution equivalent concentration of 40 lM of
CLDIs (14). After 24 h post-CLDI incubation, cells were gently
scraped and suspended in sterile flow cytometry tubes at a den-
sity of 23 106 cells/mL of PBS1 5% FBS. The cells were ana-
lyzed on a MoFlo
VR
AstriosTM (Beckman Coulter, Brea, CA)
using various laser combinations. Unless otherwise mentioned,
forward and side scatter were measured using the 488-nm laser.
Laser settings are referenced in the following format—excitation
emission/bandwidth in nm. For example, if the excitation laser
used is 488 nm and the emission detector is at 576 nm with a
bandwidth of 21 nm, the written format is 488 576/21. To check
the activity of viability dyes and signal compensation, just prior
to analysis, propidium iodide (PI) (00-6990-50; Affymetrix
eBioscience, San Diego, CA) or DAPI (D1306; Life Technolo-
gies, Grand Island, NY) was added to the cells (5 lL/1 3 106
cells). All gating and analysis was carried out on at least 10,000
cells (DAPI(2) or PI(2) cell population for viability studies)
using FlowJo (FlowJo, LLC, Ashland, OR). MIFlowCyt-
compatible information for this experiment has been included
in the Supporting Information Document (pages 5–11). Statis-
tical analysis of sensitivity and specificity was conducted by
acquiring >6 brightfield microscopy images of sorted cell pop-
ulations on standard microscopy slides and >350 cells were
counted for each sorting experiment. Sensitivity and specificity
were calculated as follows.
Sensitivity ¼ TP
TP1FN
Specif icity ¼ TN
TN1FP
where TP (true positive)5CLDI(1) in CLDI(1) cell
population,
FP false positiveð Þ ¼ CLDIð2Þ in CLDIð1Þ cell population;
TN true negativeð Þ ¼ CLDIð2Þ in CLDIð2Þ cell population;
FN false negativeð Þ ¼ CLDI 1ð Þ in CLDIð2Þ cell population:
Peritoneal Lavage
Peritoneal lavage was done as previously reported before
and after the initiation of CFZ or vehicle treatment (1 2, 4, 8,
and 16 weeks [8 weeks drug feed1 8 weeks washout phase])
(16). Mice were euthanized as described above followed by
sterilization of the outer skin with 70% of ethanol. A small
incision was made along the midline of the abdomen followed
by abdominal skin retraction up to the thoracic boundary and
the animal extremities to expose the intact peritoneal wall. A
smaller incision was then made on the peritoneal wall to
expose the cavity. The entire peritoneal cavity was washed
with ice-cold sterile PBS1 5% of FBS (5–10 mL) and col-
lected as peritoneal exudate. The exudate was then centrifuged
(100g for 5 min, 48C) and resuspended in 1.5 mL of PBS1 5%
of FBS. Cells were counted using a hemocytometer for viable
cells using Trypan Blue and for CLDI-containing cells.
Alveolar Lavage
Mice were euthanized as described above and the trachea
was surgically exposed and cannulated with an 18G luer stub
and the lungs were lavaged to obtain alveolar exudate by
instilling calcium- and magnesium-free Dulbecco’s PBS
(DPBS) containing 0.5 mM of EDTA in 1 mL aliquots for a
total of 6 mL. The alveolar exudate fluid was centrifuged
(400g, 10 min, 48C) and resuspended in RPMI 1640 media.
Viable (using Trypan Blue staining method) and CLDI-
containing cells were counted using a hemocytometer.
Flow Cytometry of Peritoneal and Alveolar Exudate
Peritoneal and alveolar lavage was performed as stated
before to obtain the respective exudates. Purified Fc block
CD16/32 (1 lL) was added for every 100,000 cells for analysis.
For CLDI fluorescence signal experiments, cells were pelleted
by centrifugation (100g for 5 min) followed by resuspension
in PBS1 5% of FBS (500 lL). For functional assays, antibod-
ies—anti-F4/80-eFluor 450 (48-4801, Affymetrix eBioscience,
San Diego, CA), anti-CD86-FITC (553691, BD Biosciences,
San Jose, CA), anti-CD206-FITC (141704, BioLegend
VR
, San
Diego, CA), anti-CD11c-eFluor450 (48-0114, Affymetrix
eBioscience), and anti-Ly6G-eFluor450 (48-5931, Affymetrix
eBioscience)—were added to the cell suspension at a loading
of 1 lg/100,000 cells (volumetric ratio, 1:10) and incubated in
the dark (30 min, 48C). After incubation, the samples were
diluted with PBS and pelleted by centrifugation (100g, 5 min).
The supernatant was discarded and the pellet was resuspended
in 300 lL of PBS1 2% of FBS. Just prior to analysis, PI (5 lL/
1 3 106 cells) was added to the cells to assess viability. Sample
measurements were carried out on a MoFlo
VR
AstriosTM EQ.
All gating and analysis was done on at least 10,000 live cells
(PI(2) cell population) using FlowJo. CLDI(1) cells were
gated either using 640 671/30 or 640 795/70. A small subpo-
pulation of CD206(1) cells, which was present in both
CLDI(1) F4/80(2) and CLDI(2) F4/80(1) populations,
exhibited high CD206 expression based on the intensity of the
fluorescence signal. These cells also had extremely high side
scatter that were measured as saturated signals. This small
subpopulation of cells was not considered for the evaluation
of change of CD206 expression in the peritoneal macrophages.
MIFlowCyt-compatible information for this experiment has
been included in the Supporting Information Document
(pages 5–8, 12–17).
Laser-Scanning Confocal Microscopy
CLDI-treated RAW264.7 cells were generated as men-
tioned above but on cover-slips in a six-well plate. The cells
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were washed with PBS buffer after which Hoechst 33342
(Invitrogen, Carlsbad, CA) and FM
VR
1-43 (Molecular Probes
T35356, Invitrogen) were used to stain cell nuclei and the
plasma membrane, respectively. Cells were incubated with 1:1
v/v of dye mixtures of 5 lg/mL Hoechst 33342 and 7 lM FMV
R
1-43 in HBSS (300 lL) for 15 min at room temperature. The
confocal imaging of the live cells was performed on an Olym-
pus Fluoview 500 (Olympus America, Center Valley, PA) using
lasers for DAPI (405 450/50), FITC (488 525/50), and Cy5
(640 671/30) channels. Z-stack images of the cells were cap-
tured along the Z-axis (interval, 0.25 lm) and analyzed using
the Nikon NIS-Elements 3.2 software (Nikon Instruments,
Melville, NY). For peritoneal macrophages stained with F4/80,
a drop of the stained cell sample was mounted on a blank
microscopy slide; Prolong Gold and a cover-slip were applied
followed by immediate scanning.
Data Plotting and Statistical Analysis
Plots were constructed using Origin 9.0 (OriginLab,
Northampton, MA) and laid out in figure format using scal-
able vector graphics format (svg) in either Inkscape (www.ink-
scape.org) or GIMP (www.gimp.org). Flow cytometry plots
were obtained in svg format directly from FlowJo and
assembled using Inkscape. All statistical analysis was per-
formed using Student’s t-test in MS-Excel. Correlation statis-
tics were done using a Pearson’s test in Origin 9.0. The results
were considered significant if P 0.05. MIFlowCyt compatible
information was prepared using established standards (17).
The completed MIFlowCyt checklist along with full gating
strategies, machine information, and data analysis has been
included in the Supporting Information Document. All origi-
nal list mode files have been saved onto internal servers and
can be obtained via email from the authors.
RESULTS
Fluorescence Spectral Analysis of CFZ and CLDIs
The fluorescence excitation and emission scan of CFZ
dissolved in DMSO indicates that CFZ in solution is fluores-
cent in the range—excitation: 540–560 nm, emission: 560–
600 nm (Fig. 1A). To characterize the fluorescence of CFZ
crystallized as a free-base triclinic crystal (closest triclinic
polymorph of neutral CFZ crystal, CCDC refcode: DAK-
XUI01), we used spectral confocal microscopy on individual
CFZ-TC crystals dispersed on a microscopy slide. CFZ-TC has
a similar fluorescence profile as soluble CFZ (Fig. 1B). How-
ever, residual fluorescence of CFZ-TC is also detected at lower
(Ex, 480–500 nm; Em, 510–540 nm) and higher (Ex, 580–
600 nm; Em, 600–640 nm) spectral ranges. To characterize
and identify a specific spectral signature associated with the
intracellularly accumulated and crystallized CLDIs, the spleens
of 8-week drug-fed mice were harvested and CLDIs were iso-
lated and purified. By visual inspection, CLDIs were dark red,
rod-shaped particles that were distinct from the orange–red
CFZ-TC crystals (Figs. 1B and 1C, inset photographs). When
subjected to fluorescence spectral analysis using the spectral
Figure 1. Fluorimetric analysis of (A) CFZ dissolved in DMSO (20 lM) done using conventional solution fluorimetry (bottom, chemical for-
mula of CFZ), (B) CFZ-TC (bottom, representative picture, scale bar5 10 lm), and (C) isolated CLDIs from spleen (bottom, representative
picture, scale bar5 10 lm) acquired using spectral confocal microscopy. The excitation wavelength (nm, Ex) and emission wavelength
(nm, Em) are shown on the X-axis and Y-axis, respectively. The normalized fluorescence yield is shown by a contour plot that was normal-
ized to the maximum measured fluorescence yield. Both solubilized CFZ in DMSO and CFZ-TC had peak fluorescence yield at Ex: 540–
570 nm, Em: 560–580 nm, whereas CLDIs had peak fluorescence yield at Ex: 560–600 nm, Em: 640–700 nm. The excitation/emission combi-
nation for the detection of commonly used fluorophores: FITC, Cy3, Texas Red, 7-AAD, APC, and Cy5 is also shown as dotted bounded
shapes superimposed on the contour plots. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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confocal microscope, CLDIs exhibited a red-shift in their
emission fluorescence spectra with peak fluorescence activity
at Ex5 560–600 nm, Em5 650–690 nm (Fig. 1C). To place
this specific red-shift in the context of other commonly used
dyes, CFZ-TC exhibited a fluorescence profile similar to FITC,
Cyanine 3 (Cy3), Rhodamine, and Texas Red (TR), whereas
CLDIs had a red-shifted fluorescence profile similar to TR,
Cyanine 5 (Cy5), 7-Aminoactinomycin D, (7-AAD), Allophy-
cocyanin (APC), and other commercial Cy5 derivatives.
Identification of CLDI-Containing Cell Subpopulations
with Standard Flow Cytometer Configurations
To design a single-cell analysis technique to study the
pharmacology of xenobiotic-sequestering macrophages and
the impact of CLDIs on cellular functions, we proceeded to
determine whether flow cytometery could be used to distin-
guish between cells that contain and do not contain CLDIs.
The samples were analyzed using standard excitation lasers
and detector configurations to determine the specific flow
cytometry settings that can be used for analyzing CLDI-
containing cell subpopulations and to establish any spectral
overlap (Fig. 2). The use of ultraviolet (355 nm) and violet
(405 nm) excitation lasers resulted in the detection of single
populations at all emission detector settings, corresponding to
the background autofluorescence signal of unlabeled cells.
Similarly, a single-cell population was detected when the sam-
ples were excited with the blue (488 nm) or green (561 nm)
excitation lasers at emission detection of <600 nm. However,
Figure 2. Flow cytometric analysis of RAW264.7 incubated with CLDIs using a variety of laser combinations on a MoFlo Astrios. (top left
inset) The forward scatter versus the side scatter used for further analysis. Various subplots are arranged based on excitation and emission
wavelength combination in the main graph (X-axis5 excitation wavelength, Y-axis5emission wavelength). A single population is observed
with RAW264.7 cells alone (shown in gray histogram in each subplot). A single population is observed with RAW264.7 cells with CLDIs when
excited with UV laser (excitation5 355 nm, all emission detector settings), violet laser (excitation5405 nm, all emission detector settings),
blue laser (excitation5488 nm, emission5513 nm, 576 nm), and orange laser (excitation5561 nm, emission5 579 nm). In all other laser
combinations, two populations were observed (labeled 1 and 2). (bottom) Confocal microscopy of RAW264.7 incubated with CLDIs con-
firmed the phagocytosis of CLDIs using the fluorescence of CLDIs in the Cy5 channel, whereas cells were stained with membrane stain FM 1-
43 (green) and nuclear counterstain Hoechst 33342 (blue) (scale bar510 lm, dotted lines show the visualization planes for the three orthogo-
nal views). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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at emission detection of >600 nm, two distinct cell popula-
tions were observed, one which corresponded to the back-
ground fluorescence signal of CLDI-free cells (labeled 1), and
the other which corresponded to the positive fluorescence sig-
nal of the CLDI-containing cells (labeled 2). Furthermore, the
use of the red (592 nm) and far-red (640 nm) excitation laser
resulted in the detection of two cell subpopulations corre-
sponding to the CLDI-free and CLDI-containing cells, at all
tested emission detector settings. The laser and detector set-
tings that detected the subpopulation of CLDI-containing
cells corresponded to the CLDI fluorescence spectra, which
were independently measured using the spectral confocal
microscope (Fig. 1C).
To confirm these observations, a fluorescence-activated
cell sorting experiment was performed using 488 664/22, 561
692/75, and 640 671/30 [See italicized statement in Methods
and Supporting Information containing MIFlowCyt information
on description of laser settings] along with laser-scanning con-
focal microscopy of incubated cells. When RAW264.7 cells
incubated with CLDIs and labeled with fluorescent cellular
staining dyes—Hoechst 33342 (nucleus) and FM 1-43 (plasma
membrane) were imaged, the intracellular accumulation of
CLDIs was confirmed via their far-red fluorescence (Fig. 2,
bottom) distinct from the green fluorescence of FM 1-43 and
blue fluorescence of Hoechst 33342. Additionally, as per
brightfield microscopy, the sorted cell population with the
lower fluorescence signal corresponded to CLDI-free cells,
whereas the sorted cell population within the high fluores-
cence signal corresponded to CLDI-containing cells (Fig. 3A).
The sorting sensitivity was 98.34, 98.82, and 99.01% at 488
664/22, 561 692/75, and 640 671/30, respectively, whereas
sorting specificity was 86.30, 90.80, and 93.98%, respectively
(for formula, see Materials and Methods section). The detec-
tion of CLDIs in subsequent flow cytometry experiments was
done using either 640 671/30 or 640 795/70, whereas for
microscopy, CLDIs were detected using the red laser (excita-
tion, 640 nm; emission, 670 nm).
Functional Flow Cytometric Analysis of Live Versus
Dead, CLDI-Containing Cells
In flow cytometry experiments, a fundamental functional
assay involves discriminating live and dead cells using stand-
ard fluorescent labels. Accordingly, to determine whether
CLDI-containing cells were viable, RAW264.7 cells loaded
with CLDIs were further incubated with membrane imperme-
ant cell viability dyes—PI or DAPI prior to flow cytometric
analysis. Using the laser-detector settings for PI—561 614/20,
two populations were detected using CLDI-incubated
RAW264.7 cells. We conducted a compensation of the spectral
overlap that was observed at 561 614/20 to verify that PI can
be used in the presence of CLDIs (at 640 671/30) without sig-
nal overlap (Fig. 3B). Incubating control (CLDI free) cells
with PI yielded two distinct cell populations, corresponding
to live (low fluorescence signal) and dead (high fluorescence
signal) cells (Fig. 3B). In contrast, after CLDI-containing cell
samples were incubated with PI, four populations were
Figure 3. (A) Representative images of brightfield microscopy of sorted cell populations—labeled 1 and 2 in Figure 2 at 488 664/22, 561
692/75, and 640 671/30, scale bar550 lm. Inset photographs show digitally zoomed-in regions (scale bars510 lm). Flow cytometric com-
pensation to obtain accurate readout of RAW264.7 cells incubated with CLDIs for viability using (B) PI and (C) DAPI. Y-axis—640 671/30. X-
axis—corresponding compensated fluorescence axes for determining PI and DAPI fluorescence. Four populations were observed with the
use of PI and DAPI to verify that viability of cells could be studied with appropriate compensation. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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observed, corresponding to viable CLDI-free (Live CLDI(2))
and viable CLDI-containing cells (Live CLDI(1)), and dead
CLDI-free (Dead CLDI(2)), and dead CLDI-containing cells
((Dead CLDI(1)) (Fig. 3B, Supporting Information Fig. S2).
In the same manner, flow cytometric analysis revealed that
DAPI could be used to determine the viability of cells contain-
ing CLDIs (Fig. 3C). With DAPI, four distinct populations
were observed (without compensation), corresponding to live
(weak signal) and dead (strong signal), CLDI containing
(marked as CLDI(1)) and CLDI-free (marked as CLDI(2))
cells. Thus, both PI and DAPI were suitable as fluorescent
markers for discriminating between live and dead cell subpo-
pulations of CLDI-containing cells.
In Vivo Flow Cytometry Detection of CLDI-Containing
Cells in Peritoneal and Alveolar Exudates from CFZ-
Treated Mice
To measure the presence of CLDIs in peritoneal exudates
obtained from CFZ-treated mice, we performed a quantita-
tive, flow cytometric analysis on peritoneal exudate of mice
after 8-week drug administration. The control mouse perito-
neal exudate showed two distinct populations (Fig. 4A, labeled
1 and 2) at all tested laser settings while the CFZ mouse peri-
toneal exudate showed two populations when assayed with
the 405 448/59 or 488 513/26 laser-detector combination.
With the use of 532 576/21, 592 620/29, 640 671/30, and 640
795/70, however, three distinct populations were observed
(Fig. 4A, labeled 1–3). The mean fluorescence intensity of
Population 3 was increased >100-fold relative to Population 1
at 640 671/30 and 640 795/70. To confirm that the third popu-
lation was CLDI(1) cells, we sorted the cell populations
labeled 1 and 3 using the 640 795/70 laser-detector combina-
tion and plated them in cell culture media overnight. Popula-
tion 1 was confirmed to be CLDI(2) cells, whereas
Population 3 was indeed CLDI(1) cells (Fig. 4B).
Next, we proceeded to determine whether the time course
of CLDI accumulation in macrophages as determined by flow
cytometry corresponded to the expected time course of CLDI
accumulation after drug treatment (2,3). After drug treatment
of mice for varying time periods, peritoneal exudates were
obtained and analyzed by flow cytometry as well as light
microscopy, revealing that CLDIs were not present at 1 and 2
weeks, but could be detected starting at 4 weeks (Fig. 4C).
To determine whether flow cytometry could be used to
characterize the molecular phenotype of CLDI-containing mac-
rophage subpopulations, multistain flow cytometry was con-
ducted on peritoneal exudates of CFZ-treated animals. For this
purpose, cells obtained from peritoneal exudates were incubated
with other commonly employed macrophage-targeted antibod-
ies possessing fluorescent signals distinct from that of CLDIs
(405 448/59 and 488 513/26; Fig. 1). As CLDI accumulation has
been reported to be macrophage targeted (3,18–20), we chose
the murine pan-macrophage marker F4/80 as well as other mac-
rophage phenotype surface markers—CD86 and CD206 (Fig.
5). The schematic representation for the quantification of the
gating strategy is shown in Figures 5A and 5B and Supporting
Information Figure S1. The analysis revealed that in peritoneal
exudates, CLDIs were primarily localized to F4/80(1) perito-
neal macrophages (PMU) (>85% of total CLDI(1) cells at all
measured time points, Fig. 5B, no statistically significant
changes across the times measured). This observation was also
confirmed via laser-scanning confocal microscopy using the far-
red fluorescence region for CLDIs and the violet laser to
visualize F4/80 extracellular membrane staining (Fig. 5B). The
accumulation, however, was both treatment and time depend-
ent with respect to F4/80(1) PMU as 38% of F4/80(1) PMU
were CLDI(1) after 4 weeks of CFZ treatment which increased
to 61% after 8 weeks (P< 0.05) of treatment and declined to
25% at 8 weeks of washout (P< 0.05; Fig. 5C(i)). Within F4/
80(1) CD86(1) cells, CLDI accumulation increased in a time-
dependent fashion, from 31% after 4 weeks of CFZ treatment
to 95% at 8 weeks1 8 weeks washout (P< 0.05, Fig. 5C(ii)).
As a proportion of F4/80(1) CD206(1) cells, CLDI(1)%
increased from 15% after 4 weeks of CFZ treatment to 93%
after 8 weeks1 8 weeks washout (P< 0.05, Fig. 5C(iii)). Collec-
tively, these findings suggest that CLDI accumulation was not
restricted to the CD86(1) or CD206(1) macrophage pheno-
type (Fig. 5B). In a related trend, % CLDI(1) cells that could
be identified as F4/80(1) CD86(1) increased from 38% at
4 weeks post-drug feeding to 70% at 8 weeks1 8 weeks wash-
out (P< 0.05), whereas % CLDI(1) cells that could be identi-
fied as F4/80(1) CD206(1) increased from 20% at 4 weeks
post-drug feeding to 81% at 8 weeks1 8 weeks washout
(P< 0.05). Although the accumulation of CLDIs in CD86(1)
cells was higher relative to CD206(1) cells at 4- and 8-week
post-drug feeding (P< 0.05), the accumulation was not statisti-
cally deviated toward any phenotype at 8 weeks1 8 weeks
washout (P> 0.05). In contrast, the ratiometric CD86 median
surface expression in CLDI(1) relative to CLDI(2) decreased
from 1.17 at 4-week post-drug feeding to 0.95 (P< 0.05,
Fig. 5C(iv)) at 8-week post-drug feeding. The ratiometric
CD206 median surface expression in CLDI(1) relative to
CLDI(2) CD206 remained between 0.97 and 1.15 for
CD206 with no statistically significant difference at the three
measured time points (Fig. 5C(iv)). As the fold change in the
median surface expression is much less than the benchmark of
twofold change in expression to ascertain significant change in
the expression of the two surface markers—the changes, as a
result of being CLDI(1), reflect relatively minor expressional
differences between the two populations. Finally, the viability of
F4/80(1) cells, as measured via PI(2) cells, was unaffected by
the presence of CLDIs (viability of CLDI(1) F4/
80(1)5 876 6%, CLDI(2) F4/80(1)5 886 12%, P5 0.84
between the two groups, n5 4). The viability measured via flow
cytometry also agreed with the sample viability of CLDI1 cells
in the peritoneal exudate measured by Trypan blue staining
(876 9%, n5 4).
To follow up our analysis on peritoneal exudate, we per-
formed a flow cytometric analysis on alveolar exudate of
drug-fed mice at 8 weeks to confirm the macrophage-specific
accumulation of CLDIs in the lung (2,4,18) (Fig. 6). Both the
control and the CFZ mice alveolar exudates had two distinct
populations. However, Population 2, that had high side scat-
ter, had a distinctly higher fluorescence at the settings used to
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detect CLDIs (640 671/30), marking them out as CLDI(1)
cells. Upon further testing with fluorescent antibodies (at 405
448/59), specific for alveolar macrophages (CD11c) and neu-
trophils (Ly6G) (21), CLDI(1) cells were determined to be
overwhelmingly CD11c(1) (>99%), whereas <2% of
Ly6G(1) cells were detected as CLDI(1).
Figure 4. (A) Flow cytometric analysis of peritoneal exudate in control mice and CFZ-treated mice done using various laser combinations.
Two distinct populations were observed in the control peritoneal exudate (labeled 1 and 2) and at 405 448/59 and 488 513/26 in the CFZ
peritoneal exudate, whereas three populations were observed at 532 576/21, 592 620/29, 640 671/30, and 640 795/70 and two populations
were observed. The Y-axis shows the side-scatter profile of cells in which high side-scatter is associated with peritoneal macrophages and
low side scatter is associated with B lymphocytes. (B) The populations labeled 1 and 3 at 640 795/70 in (A) were sorted, plated with com-
plete growth media, and visualized using standard epifluorescence microscopy. Population 3 shows a remarkably high proportion of cells
containing CLDIs; Population 2 are cells containing no CLDIs (scale bar5100 lm). Inset photographs show digitally zoomed regions (scale
bar550 lm). (C) Flow cytometric analysis of peritoneal exudate at various time points post-drug feeding. Y-axis in each plot is the side-
scatter profile, whereas the X-axis is the 640 795/70 laser-detector combination. CLDI(1) cells are observed starting at 4 weeks of CFZ treat-
ment. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Correlation of CLDI Amount with Mean Cellular
Fluorescence Intensity
In fluorescence activated cell sorting experiments,
attempts to relate the mean cellular fluorescence intensity
(MFI) of sorted cell populations with the total number of
CLDIs per cell did not yield interpretable data. Therefore, to
determine whether the fluorescence signal per cell was related
to the number of CLDIs in each cell, we incubated RAW264.7
macrophage cells with CLDIs, and acquired fluorescence
images with conventional epifluorescence microscopy using
the Cy5 filter for CLDIs (Supporting Information Fig. S3).
The normalized background-corrected MFI of cells were
Figure 5. (A) Flow cytometry analysis of peritoneal exudate in CFZ mice. Gating was done via viability using PI (compensated 561 614/10
settings) and then for CLDI-associated signal at 640 795/70. (B) The peritoneal exudate was also dual labeled with antibodies for the pan-
macrophage marker F4/80 (detected using 405 448/59) followed by either CD86 or CD206 (488 513/26). Gating for CLDI(1) followed by F4/
80(1) and CD86(1) or CD206(1) is shown. CLDI(2) cells were significantly F4/80(1) with a medium expression of CD86 and CD206. Gating
for antibody positivity was done via the corresponding isotype (gray background histogram). Confocal microscopy shows the membrane
staining of the F4/80 surface marker in blue, whereas CLDIs are shown in red (scale bar5 10 lm, dotted lines show the visualization planes
for the three orthogonal views). (C) Cumulative statistics on CLDI(1) cells that are (i) F4/80 (1) , (ii) CD86 (1) , and (iii) CD206 (1) in CFZ
mice at 4, 8, and 8 weeks18 weeks washout (8 weeks wo) post drug feeding (schematic representation for quantification shown in Sup-
porting Information Fig. S1). (iv) Median expression of CD86 and CD206 in CLDI (1) F4/80(1) relative to CLDI(1)F4/80(1) were also com-
pared at all time points. *P< 0.05 (Student’s t-test). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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strongly correlated (Pearson’s r5 0.70, P< 0.0001) with the
number of CLDIs/cell. As expected, cell MFI was uncorrelated
to intracellular CLDI geometry and morphology (Supporting
Information Fig. S4, Pearson’s r520.2 to 0.3, P< 0.005).
The resulting fluorescence signal readily distinguished
CLDI(1) cell relative to a CLDI(2) cells (P< 0.005, Support-
ing Information Table S1). Cells containing 1 versus 2 CLDIs
were also distinguishable (P< 0.05). However, cells containing
>2 CLDIs could not be distinguished from cells containing
fewer CLDIs. Given that each CLDI contains 25 fmol of
CFZ (24.36 13.5, n5 8 mice), we infer that this method
could be used to quantify CFZ sequestration in CLDIs, up to
50 fmol of CFZ (corresponding to two CLDIs per cell).
DISCUSSION
The pharmacological activity of CFZ, its pharmacokinetics,
and its effectiveness as an antimycobacterial agent have been
intensively studied for several decades (1,22–28). Remarkably,
the optical properties of CFZ have been largely unrecognized,
especially in the context of its intracellular bioaccumulation
behavior. Although CFZ’s accumulation in CLDIs has been clin-
ically observed, the phenotypic characteristics and the mecha-
nisms that underlie such massive intracellular bioaccumulation
have not been studied (2,7,18,19,26,29). Seeking to understand
whether the intracellular bioaccumulation of CFZ affects the
optical properties of the drug, we determined whether there are
spectral shifts in fluorescence excitation and the emission spec-
trum of CLDIs in relation to the soluble form of the drug. As a
reference, CFZ was readily crystallized as a free base—CFZ-TC
(CCDC ref code: DAKXUI01) and the spectrum of the CFZ-TC
crystals was analyzed and compared to that of CLDIs. Using a
spectral confocal microscope imaging system, fluorescence spec-
tral analysis was carried out on CLDIs, and compared to the flu-
orescence spectra of pure crystalline forms of CFZ, resulting in a
red shift in the fluorescence emission spectra in CLDIs. This flu-
orescence shift led to a highly specific signal that was largely con-
fined to channels that are used to detect far-red probes such as
Cyanine 5-like fluorescence either in Cyanine 5 (Cy5) or its vari-
ous commercial conjugates in standard epifluorescence micro-
scopes filter setups and flow cytometers. Surprisingly, although
CFZ and CFZ-TC have strong fluorescence in the green to mid-
red fluorescence range, CLDIs exhibited a pronounced, red-
shifted fluorescence emission profile, spanning the red to far-red
range of the visible spectrum. Unlike CLDIs, both CFZ and
CFZ-TC exhibited some fluorescence in the blue–green wave-
lengths of the electromagnetic spectrum.
To assess the utility of the far-red fluorescence activity of
CLDIs, we proceeded to detect the fluorescence signal with a
flow cytometry approach using different lasers on a
macrophage-derived cell line that is known to internalize CLDIs
through phagocytosis. Inside cells, the fluorescence of CLDIs
Figure 6. Flow cytometric analysis of alveolar exudate at 8-weeks post-drug feeding. PI fluorescence was detected using the compensated
561 614/20 laser-detector setting whereas CLDI fluorescence was detected using the 640,671/30 setting. Gating was done on live cells fol-
lowed by CLDI(1) cells. The population labeled 2 in orange color showed significant CLDI signal marking them out as CLDI(1) cells. The alve-
olar exudate was also labeled with antibodies for the macrophage surface marker CD11c (detected using 405 448/59) or the neutrophil
surface marker Ly6G (detected using 405 448/59). CLDI(1) cells were overwhelmingly CD11c(1) (>99%, six pooled mice lavage sample,
repeated twice) and Ly6G(2) (six pooled mice lavage sample, repeated twice). Gating for antibody positivity was done using the correspond-
ing isotype (gray background histogram). [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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was specific to the red and far-red fluorescence spectral chan-
nels, corresponding to the fluorescence spectra obtained with
the spectral confocal microscope. The accuracy and sensitivity
of the flow cytometer for detecting CLDI(1) cells from a mixed
population of cells was calculated to be >98% sensitive and
>93% specific. Owing to minimal spectral overlap in the ultra-
violet, violet, blue, and green fluorescence channels, CLDIs can
be readily used as a marker for xenobiotic sequestering macro-
phages, for multicolor flow cytometric analysis with orthogonal
fluorescent probes and cellular staining dyes for microscopic
analysis and image cytometry (30).
Proceeding to analyze the phenotypic characteristics of
xenobiotic sequestering PMU and alveolar macrophages
(AMU) that bioaccumulate CFZ upon prolonged oral feed-
ing in mice, we confirmed that the laser detector combina-
tion of 640 671/30 or 640 795/70 could be used to identify
CLDI(1) cells. Three populations were observed (Fig. 4)
with the peritoneal exudate. Populations 1 and 2 were of
high side scatter and low side scatter, respectively, but had
low fluorescence. Earlier reports have characterized that peri-
toneal exudates contain primarily PMU and B cells (16,31).
Based on the scatter analysis, Population 1 was most likely
PMU, whereas Population 2 contained B cells. Population 3
had high side scatter as well as high fluorescence, indicating
that they were CLDI(1) cells as well as most likely a PMU
cell population. This was confirmed by sorting the fluores-
cent and nonfluorescent cell populations, plating the corre-
sponding populations on tissue culture dishes, and visually
inspecting them for the presence or absence of CLDIs. In the
alveolar exudate, two distinct populations were observed for
both control and CFZ mice samples. The high side-scatter
population was identified to contain CLDIs owing to the
high-fluorescence signal detected with that population in the
CFZ mice samples, identifying it as a potential AMU popu-
lation as well.
Murine resident PMU as well as macrophages of others
organs have high F4/80 plasma membrane expression (32).
F4/80 is encoded by the gene Emr1, a member of the
adhesion-GPCR family of proteins that play notable roles in
immune modulation and related functions (33) (www.gene-
cards.org). Based on the expression of other surface markers,
these macrophages can be classified into two specific func-
tional categories—classically activated macrophages (M1) and
alternatively activated macrophages (M2) (12,34–38). M1
macrophages noticeably express high levels of the cell-surface
marker CD86 that is critical for host defense but can also be
harmful to the host (36,37). M2 macrophages express high
levels of CD206 and are key mediators of host inflammation
via the their wound healing, tissue remodeling, and angio-
genic functions (34,35). Most importantly, both CD86 and
CD206 are exclusive to M1 and M2 type macrophages, respec-
tively, serving as important biomarkers for inflammation-
related events. With the use of the CLDI-specific signal, we
confirmed that the majority of the CLDI(1) cells were indeed
F4/801 PMU (>85%) and the presence of CLDIs had a minor
effect on polarizing the macrophages toward the M2 pheno-
type (34).
Analyzing the alveolar exudate, CLDI accumulation was
specifically targeted toward CD11c(1) cells (>99%), whereas
Ly6G(1) cells had negligibly low CLDI accumulation. Alveo-
lar exudates from healthy humans (39) and mice (40) typically
contain AMU, neutrophils, and lymphocytes. CD11c is an
integrin protein, encoded by the gene ITGAX, with useful
functions in cell–cell interactions during inflammation as well
as in macrophage adhesion and chemotaxis (www.genecards.
org). CD11c is also an important surface cell marker for evalu-
ating murine AMU (CD11c(1)) (21,41,42). Ly6G is a murine
glycosylphosphatidylinositol-anchored protein with unknown
functions in cellular physiology (43). It is also a neutrophil-
specific surface marker that has been used to examine inflam-
mation models in various tissues (21,44,45). Using these spe-
cific immune markers for macrophages and neutrophils,
CLDI accumulation was confirmed to be mostly present in
AMU.
Like other fluorescent probes that emit in the far-red or
infrared regions of the electromagnetic spectrum (46,47), the
intrinsic fluorescence of CLDIs exhibits favorable optical
properties (47), with minimal background fluorescence in the
far-red and near infra-red region allowing accurate quantita-
tive analysis with the flow cytometer or fluorescence micro-
scope (48). Accordingly, these results demonstrate that CFZ,
when stabilized as CLDIs, has excellent properties as a fluores-
cent probe for characterizing the specific macrophage subpo-
pulations involved in xenobiotic disposition. As with other
fluorescence-based measurement method, this fluorescence
signal was saturatable, although there was a significant corre-
lation between the fluorescence signal of the cells and the
number of CLDIs per cell for cells containing 0, 1, or 2 CLDIs,
the correlation was lost for cells containing three or more
CLDIs. Nevertheless, the specific fluorescence signal of CLDIs
could serve as an all-or-none probe for detecting and sorting
xenobiotic sequestering macrophages, and as a tracking probe
to follow the function of these cells during inflammation and
wound healing. Considering that recent studies have pointed
out the therapeutic efficacy of CFZ for drug-resistant tubercu-
losis, the potential application of CLDIs as cellular-targeted
probes for the assessment of antimycobacterial activity is
promising (49–54). In terms of the functional significance of
these xenobiotic sequestering macrophages, other poorly solu-
ble drugs, endogenous metabolites, and toxins have been
reported to bioaccumulate within macrophages. Such bioac-
cumulating agents are often associated with a macrophage
activation phenotype, favoring the M1 population which was
not observed in the case of the CLDI-containing cells (9–12).
Using a fluorescence-activated cell sorter, the isolation of
CLDI(1) cell subpopulations will enable a precisely quanti-
fied approach toward understanding the mechanisms of xeno-
biotic sequestration.
CONCLUSIONS
In summary, the analysis of macrophage populations in
vitro and ex vivo was made possible owing to the unique fluo-
rescence spectral characteristics of CLDIs relative to neutral
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free base CFZ precipitates as well as the CFZ molecule in solu-
ble form. The specific fluorescence of CLDIs was utilized in
single-cell flow cytometry to study macrophage-related intra-
cellular drug accumulation wherein we were able to measure
macrophage functions including viability and expression of
different cell surface markers, by exploiting the unique fluo-
rescence spectrum of CLDIs and the availability of many other
orthogonal fluorescent probes that can be detected with
standard flow cytometry parameters, with minimal spectral
overlap from the CLDI signal. We also confirmed that the
presence of CLDIs has a minor polarizing effect toward the
M2 macrophage phenotype. More importantly, the unique
fluorescence shift of CFZ molecules from the freely soluble
green–blue fluorescent state to the solid far-red CLDI fluores-
cent state should facilitate analysis of the molecular mecha-
nisms driving drug accumulation and CLDI formation, using
a variety of molecular, pharmacological, genetic, or systems
biology approaches. These studies will be instrumental for fur-
thering the understanding of the role of xenobiotic sequester-
ing macrophages of the organism in response to
bioaccumulating drugs or environmental toxicants.
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